Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in ...

Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food ...

The global Targeted Protein Degradation Market, valued at US$0.01 billion in 2024, stood at US$0.48 billion in 2025 and is ...

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS – Research Report), Staar Surgical (STAA – Research Report) and Arvinas Holdin ...

US FDA accepts Arvinas’ NDA for vepdegestrant to treat ESR1m, ER+/HER2- advanced breast cancer: New Haven, Connecticut Monday, August 11, 2025, 17:00 Hrs [IST] Arvinas, Inc., a ...

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced ...

In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, ...

Final Takeaway Arvinas approaches a pivotal period as it executes on a streamlined operations strategy, extends its cash runway into the second half of 2028, and manages a CEO transition.